Israel’s Brain.Q (see here previously) has received the CE-Mark for its BQ 2.0 system, designed to reduce disability following ischemic stroke, the number one cause of disability worldwide. Brain.Q is also enrolling in the EMAGINE II pivotal study to seek US-FDA clearance.
European approval for stroke therapy
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.